125 related articles for article (PubMed ID: 36088873)
1. Synthesis and evaluation of a para-carboxylated benzyl-DOTA for labeling peptides and polypeptides.
Suzuki H; Ichinohe K; Araki M; Muramatsu S; Uehara T; Arano Y
Nucl Med Biol; 2022; 114-115():18-28. PubMed ID: 36088873
[TBL] [Abstract][Full Text] [Related]
2. Stability Estimation of Gallium Complexes of DOTA Derivatives for Radiotheranostic Applications.
Suzuki H; Muramatsu S; Ichinohe K; Uchimura M; Araki M; Uehara T; Arano Y
ACS Omega; 2022 Nov; 7(47):43321-43328. PubMed ID: 36467905
[TBL] [Abstract][Full Text] [Related]
3. Reduction of the hepatic radioactivity levels of [
Suzuki H; Matsukawa M; Madokoro R; Terasaka Y; Kannaka K; Uehara T
Nucl Med Biol; 2024; 132-133():108910. PubMed ID: 38636351
[TBL] [Abstract][Full Text] [Related]
4. Facile synthesis and evaluation of C-functionalized benzyl-1-oxa-4,7,10-triazacyclododecane-N,N',N″-triacetic acid as chelating agent for ¹¹¹In-labeled polypeptides.
Suzuki H; Kanai A; Uehara T; Guerra Gomez FL; Hanaoka H; Arano Y
Bioorg Med Chem; 2012 Jan; 20(2):978-84. PubMed ID: 22178661
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals.
Ferreira CL; Lamsa E; Woods M; Duan Y; Fernando P; Bensimon C; Kordos M; Guenther K; Jurek P; Kiefer GE
Bioconjug Chem; 2010 Mar; 21(3):531-6. PubMed ID: 20175523
[TBL] [Abstract][Full Text] [Related]
8. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Cancer Biother Radiopharm; 2018 Feb; 33(1):8-16. PubMed ID: 29373046
[TBL] [Abstract][Full Text] [Related]
9. A convenient and efficient total solid-phase synthesis of DOTA-functionalized tumor-targeting peptides for PET imaging of cancer.
Okarvi SM; AlJammaz I
EJNMMI Res; 2019 Sep; 9(1):88. PubMed ID: 31502101
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
11. Significance of (111)In-DTPA chelate in renal radioactivity levels of (111)In-DTPA-conjugated peptides.
Akizawa H; Arano Y; Mifune M; Iwado A; Saito Y; Uehara T; Ono M; Fujioka Y; Ogawa K; Kiso Y; Saji H
Nucl Med Biol; 2001 May; 28(4):459-68. PubMed ID: 11395320
[TBL] [Abstract][Full Text] [Related]
12. A Metal-Free DOTA-Conjugated
Roxin Á; Zhang C; Huh S; Lepage M; Zhang Z; Lin KS; Bénard F; Perrin DM
Bioconjug Chem; 2019 Apr; 30(4):1210-1219. PubMed ID: 30896929
[TBL] [Abstract][Full Text] [Related]
13. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H
Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158
[TBL] [Abstract][Full Text] [Related]
14. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide.
Maresca KP; Marquis JC; Hillier SM; Lu G; Femia FJ; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
Bioconjug Chem; 2010 Jun; 21(6):1032-42. PubMed ID: 20402463
[TBL] [Abstract][Full Text] [Related]
15. A Modular Dual-Labeling Scaffold That Retains Agonistic Properties for Somatostatin Receptor Targeting.
Ghosh SC; Rodriguez M; Carmon KS; Voss J; Wilganowski NL; Schonbrunn A; Azhdarinia A
J Nucl Med; 2017 Nov; 58(11):1858-1864. PubMed ID: 28572490
[TBL] [Abstract][Full Text] [Related]
16. Redesign of negatively charged
Oshima N; Akizawa H; Kawashima H; Zhao S; Zhao Y; Nishijima KI; Kitamura Y; Arano Y; Kuge Y; Ohkura K
Nucl Med Biol; 2017 May; 48():16-25. PubMed ID: 28160666
[TBL] [Abstract][Full Text] [Related]
17. Reduction of the Renal Radioactivity of
Suzuki H; Araki M; Tatsugi K; Ichinohe K; Uehara T; Arano Y
J Med Chem; 2023 Jul; 66(13):8600-8613. PubMed ID: 37322876
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation.
De K; Banerjee I; Misra M
Amino Acids; 2015 Jun; 47(6):1135-53. PubMed ID: 25743164
[TBL] [Abstract][Full Text] [Related]
19. Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides.
Xu LC; Nakayama M; Harada K; Kuniyasu A; Nakayama H; Tomiguchi S; Kojima A; Takahashi M; Ono M; Arano Y; Saji H; Yao Z; Sakahara H; Konishi J; Imagawa Y
Bioconjug Chem; 1999; 10(1):9-17. PubMed ID: 9893958
[TBL] [Abstract][Full Text] [Related]
20. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.
Shi J; Kim YS; Chakraborty S; Zhou Y; Wang F; Liu S
Amino Acids; 2011 Nov; 41(5):1059-70. PubMed ID: 20052508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
